Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CBIO

Crescent Biopharma Inc

Dec 05 • 04:00PM ET

13.07

+0.08 0.62 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE AXSM AFMD HOOK IMMP XFOR CDTX NERV PVLA SYBX

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-21.97	Insider Own	22.62%	Shs Outstand	13.89M	Perf Week	-13.16%
Market Cap	181.58M	Forward P/E	-	EPS next Y	-5.82	Insider Trans	0.00%	Shs Float	10.75M	Perf Month	5.15%
Enterprise Value	54.06M	PEG	-	EPS next Q	-2.44	Inst Own	69.67%	Short Float	5.40%	Perf Quarter	0.93%
Income	-55.96M	P/S	-	EPS this Y	78.89%	Inst Trans	-3.98%	Short Ratio	4.21	Perf Half Y	-32.56%
Sales	0.00M	P/B	1.61	EPS next Y	53.23%	ROA	-72.70%	Short Interest	0.58M	Perf YTD	-47.51%
Book/sh	8.11	P/C	1.36	EPS next 5Y	58.55%	ROE	-87.43%	52W High	37.00 -64.68%	Perf Year	-57.83%
Cash/sh	9.59	P/FCF	-	EPS past 3/5Y	21.89% 15.18%	ROIC	-47.44%	52W Low	9.81 33.23%	Perf 3Y	-93.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.05% 6.79%	Perf 5Y	-96.52%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	64.36%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-98.08%
Dividend Ex-Date	-	Quick Ratio	6.63	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	47.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.63	EPS Q/Q	90.23%	SMA20	-2.75%	Beta	1.33	Target Price	28.20
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	3.17%	Rel Volume	1.78	Prev Close	12.99
Employees	26	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	-24.56%	Avg Volume	138.08K	Price	13.07
IPO	Jan 10, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	35.17% -	Trades		Volume	245,924	Change	0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-25-25	Initiated	Jefferies	Buy	$26
Aug-11-25	Initiated	H.C. Wainwright	Buy	$25
Jul-14-25	Initiated	Wedbush	Outperform	$27
Jun-25-25	Initiated	Stifel	Buy	$28
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Dec-05-25 09:36AM	Crescent and Kelun-Biotech swap cancer asset rights in double deal (Pharmaceutical Technology)
05:00AM	Praxis soars higher; Bristol Myers CAR-T therapy wins broader use (BioPharma Dive)
Dec-04-25 06:35AM	Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors (GlobeNewswire)
06:30AM	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics (GlobeNewswire)
Nov-17-25 04:15PM	Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
07:40AM	Loading…
Nov-06-25 07:40AM	Crescent Biopharma: Q3 Earnings Snapshot (Associated Press Finance) +5.39%
07:30AM	Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-05-25 07:30AM	Crescent Biopharma to Present at November Investor Conferences (GlobeNewswire)
Nov-04-25 09:05AM	Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Aug-28-25 07:30AM	Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire)
Jul-31-25 07:34AM	Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
07:32AM	Crescent Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
Jul-08-25 07:30AM	Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-05-25 04:01PM	GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals (Business Wire) -5.43%
May-14-25 07:02PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance) -5.50%
07:30AM	Loading…
Apr-28-25 07:30AM	Crescent Biopharma Appoints David Lubner to Board of Directors (GlobeNewswire)
Apr-03-25 07:30AM	Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics (GlobeNewswire) -11.73%
Jan-14-25 09:34AM	GlycoMimetics and Crescent Biopharma Announce Merger Plans (TipRanks)
Nov-13-24 05:15PM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-12-24 08:00AM	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 (PR Newswire) -5.29%
Nov-06-24 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting (Business Wire)
Oct-30-24 08:31AM	GlycoMimetics Announces Merger with Crescent Biopharma (TipRanks) -6.84%
Oct-29-24 07:00AM	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma (Business Wire) +191.32%
06:30AM	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint (Business Wire)
Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
04:05AM	Loading…
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CBIO

Crescent Biopharma Inc

Upgrade your FINVIZ experience